Filgotinib in the treatment of patients with ulcerative colitis: towards precision medicine

Primary non-response and secondary loss-of-response in treatment of patients with ulcerative colitis is common, both in established and novel therapeutic options. Prediction of (non-)response using biomarkers, preferably available before starting treatment, would aid clinicians and patients in making informed choices regarding treatment strategies. We will use advanced omics analyses to examine these biomarkers.

Jonas Louwers